Maddie Olson

Maddie Olson

Company: OncoNano Medicine Inc.

Job title: Clinical Scientist


A Phase 1 Dose-Escalation & Expansion Study of Intratumorally Administered Dual STING Agonist (ONM-501) Alone & in Combination With Cemiplimab in Patients With Advanced Solid Tumors & Lymphomas 1:30 pm

Overcoming challenges of early STING Agonists Review the development and mechanism of action of dual STING agonist ONM-501 Examine phase 1 trial design and review of trial updates and safetyRead more

day: Conference Day 1

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.